PHARMACEUTICAL MANUFACTURING & MEDTECH
PHARMACEUTICAL MANUFACTURING & MEDTECH
Liverpool City Region is Europe’s most significant cluster of bio-manufacturing.
Our region is home to the world’s biggest pharmaceutical players, including; Allergan, Lilly, Elanco and Bristol-Myers Squibb. Major vaccine manufacturers, AstraZeneca and Seqirus are also based in the region and are currently playing a crucial role in helping fight the global Covid-19 pandemic.
Alongside a rapidly growing MedTech cluster in the City Region there is an increasing need to embrace digital technologies to meet unprecedented demand during a global pandemic.
CASE STUDY: ASTRAZENECA
Liverpool has a major concentration of bio-manufacturing with global players developing next generation pharmaceutical products. AstraZeneca is an example of the commitment to invest in bio-manufacturing in the region.
AstraZeneca’s biologics site in Liverpool has unique facilities to bulk-manufacture the nasal spray influenza vaccine and can produce up to 20 million vaccine doses every year. There has been £75 million of investment at the site to support increased production of the vaccine for use in the UK and internationally
AstraZeneca supplies the nasal spray vaccine as an important part of the Government’s extended childhood flu vaccination programme. Over time, as the programme rolls out, all children between the ages of two and 17 will be vaccinated against flu each year with the nasal spray made in Liverpool.
AstraZeneca is an active partner with local universities and research bodies. The Centre for Drug Safety Science at the University of Liverpool, brings together companies like AstraZeneca with regulatory authorities and academic researchers to work collaboratively on drug safety.
CASE STUDY: SEQIRUS
Seqirus, the world’s no.2 influenza vaccine provider, recently announced a £22.1 million investment for its site in Liverpool. The company, which is part of global biotherapeutics leader CSL Limited, is developing a new £15.3 million manufacturing facility to support the production of influenza vaccines at its Liverpool site, complemented by a £6.8 million warehouse which opened in early 2017. The development paves the way for the future expansion of product manufacturing at the Liverpool site, which plays an important role in Seqirus’ global operations.
CASE STUDY – STFC HARTREE CENTRE
The Science and Technology Facilities Council (STFC) Hartree Centre and Atos, global leader in digital transformation, have combined forces to provide access to the powerful Bull Sequana X1000 supercomputer to assist in global computational drug discovery efforts to help combat COVID-19.
The Hartree Centre team is working closely with Washington University School of Medicine who lead the Folding@home project, which allows a global community of contributors to lend unused background capacity on their personal computers to power simulations of target drug interactions.
The use of spare capacity on supercomputers is accelerating this process and helping to create new drug structures to be simulated fully across Folding@home’s distributed compute power.
The Atos Bull Sequana X1000 systems at the Hartree Centre are also being used to support the work of CompBioMed, the European Centre of Excellence in Computational Biomedicine, as part of a global effort which includes hundreds of researchers from across the US and Europe to tackle different aspects of Covid-19.
This requires thousands of compounds to be screened in the form of advanced simulations, demanding high levels of compute power. The Hartree Centre systems are being used as part of an exceptional array of supercomputers across the world that are being harnessed to undertake these simulations.
In 2015, a £315.5 million deal with information technology leader IBM was announced to boost big data research in the UK. Through this strategic partnership, the Hartree Centre is enabling access to the latest data-centric and cognitive computing technologies from IBM, including its world-class ‘Watson’ platform.
Delivered through the cloud, IBM’s Watson analyses high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers. One of the first projects using Watson that Hartree is leading on is a collaboration with Alder Hey Children’s Hospital to improve the patient experience by creating the UK’s first cognitive hospital.
CASE STUDY – KNOWLEDGE QUARTER
Knowledge Quarter Liverpool (KQ Liverpool) is home to the University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine and the Royal Liverpool University Hospital and is fast becoming one of the world’s leading innovation districts. Upon completion of its new hospitals, it will be one of the largest academic and clinical campuses in the UK.
With world-leading specialisms, such as the fight against infectious diseases, materials innovation, personalised medicine, digital health, sensor technology and sports science, KQ Liverpool has already distinguished itself from other competing cities.
There are over £1 billion of new developments already taking shape here across all aspects of the life sciences research and draws in expertise from other disciplines such as engineering, chemistry and computer science to develop the next generation of therapies, diagnostics, medical devices (particularly digital sensors) and care practices that are transforming human healthcare in the 21st Century.
CASE STUDY – NEEDLESMART
NeedleSmart, a creator of market leading medical technology based in Liverpool City Region are at the forefront of medical technology with their Digital Vaccination System (DVS) created to support mass vaccination programmes.
The Covid-19 crisis demands a scale, speed and level of vaccination compliance that will challenge all current vaccination protocols.
NeedleSmart’s revolutionary Digital Vaccination System (DVS) has been created to deliver a single solution that can coordinate every individual vaccination initiative into a single, coherent vaccination programme.
Their new DVS system is designed to halve appointment time, allowing twice as many vaccinations per session, automatically recording all relevant vaccination data in a secure database, delivering 100% accurate and accessible records and significantly reduce risk of Needle Stick Injury during mass vaccination programmes.
CASE STUDY – FACTORYTALK
Factorytalk are a leading supplier to the Pharmaceutical, Biotech, Medical Device, and other regulated industries. The company combines the latest technology and products, with the techniques and regulatory knowledge required to bring them to fruition in highly regulated environments.
Headquartered in Bangkok, Thailand, the company has recently set up its UK operations based in Daresbury. Factorytalk specialise in software products and consulting services for digitalisation of GxP regulated manufacturing including Electronic Batch Recording (EBR), Electronic Quality Management Systems (eQMS), Computer System Validation (CSV) and IIOT zero-code platforms for self-service manufacturing apps
Operating since 2004, Factorytalk supports customers from large global multinational pharma companies to SME manufacturers with their products enabling manufacturers to progress on the journey to industry and pharm 4.0 with agile, low effort and cost effective solutions.
Factorytalk’s quick delivery solutions help companies to remove paper management problems, reduce compliance errors and minimise the effort of creating and approving paper work instructions and by enabling easy integration with plant sensors and machines, their clients can realise the benefits and value of the data in their production.